Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4819
Source ID: NCT05544214
Associated Drug: Ckd-371
Title: Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects
Acronym: CKD-371
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type II Diabetes Mellitus
Interventions: DRUG: CKD-371
Outcome Measures: Primary: AUCt of CKD-371, D745+D759, Area under the CKD-371, D745+D759 concentration in blood-time curve from zero to final, Pre-dose(0hr), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48hr|Cmax of CKD-371, D745+D759, The maximum CKD-388/D418 concentration in blood sampling time, Pre-dose(0hr), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48hr |
Sponsor/Collaborators: Sponsor: Chong Kun Dang Pharmaceutical
Gender: ALL
Age: ADULT
Phases: PHASE1
Enrollment: 32
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2022-10-21
Completion Date: 2022-11-17
Results First Posted:
Last Update Posted: 2023-03-22
Locations: Korea University Anam Hospital, Seoul, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT05544214